Comparative Pharmacology
Head-to-head clinical analysis: FARYDAK versus ROMIDEPSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARYDAK versus ROMIDEPSIN.
FARYDAK vs ROMIDEPSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panobinostat is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs, leading to accumulation of acetylated histones and other proteins, resulting in cell cycle arrest and apoptosis in cancer cells.
Romidepsin is a histone deacetylase (HDAC) inhibitor that inhibits HDAC1 and HDAC2, leading to accumulation of acetylated histones and other proteins, resulting in cell cycle arrest and apoptosis in malignant cells.
20 mg orally once daily on days 1, 8, and 15 of a 28-day cycle.
14 mg/m2 intravenously over 4 hours on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 31-67 hours), supporting once-weekly dosing.
Clinical Note
moderateRomidepsin + Digoxin
"Romidepsin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateRomidepsin + Digitoxin
"Romidepsin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRomidepsin + Deslanoside
"Romidepsin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRomidepsin + Acetyldigitoxin
"Romidepsin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 3 hours (range 1–5 hours), supporting continuous infusion or repeated dosing schedules.
Primarily hepatic metabolism via CYP3A4, with <5% excreted unchanged in urine and <1% in feces.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~25% of total clearance.
Category C
Category C
Histone Deacetylase Inhibitor
Histone Deacetylase Inhibitor